RECBIO-B (02179) announced its annual performance with a net loss of 610 million yuan attributable to shareholders, a year-on-year increase of 8.54%.

RECBIO-B (02179) released its annual performance up to December 31, 2025, with a revenue of 127.26 million yuan; shareholders' net loss was 610 million yuan, an 8.54% increase compared to the previous year; the loss per share was 1.15 yuan. Currently, the company's vaccine portfolio consists of more than 10 vaccines, including the company's two strategic products: REC610, a new adjuvant recombinant herpes zoster vaccine, currently in the process of applying for market approval in China; REC603, a recombinant nine-valent HPV vaccine, currently in phase III clinical trials. Through the company's years of investment and focus in this area, the company has developed a comprehensive vaccine innovation engine, including a new adjuvant platform, protein engineering platform, immune evaluation platform, and process development platform. These platforms enable the company to continuously discover and develop innovative vaccines, applying advanced technologies in candidate vaccines. The company is one of the few capable of developing new adjuvants, able to benchmark against all new adjuvants approved by the FDA. The company's four major technology platforms form a synergistic effect in antigen design and optimization, adjuvant development and production, and determining the optimal combination of antigens and adjuvants. The company has also established an IPD system to simultaneously advance the development of multiple candidate vaccines. Following the company's OPTI vaccine development concept, the company has established a vaccine portfolio consisting of more than 10 candidate vaccines. The company has started to establish its production capacity at an early stage to ensure the successful commercialization of its candidate vaccines. The company has completed the construction of an HPV vaccine production base in Taizhou City, Jiangsu Province, meeting WHO PQ pre-qualification standards, with a designed capacity of 20 million doses of nine-valent HPV vaccine per year. It is currently in the trial production stage, matching the progress of nine-valent HPV vaccine clinical studies to support a Chinese BLA application. In addition, the company completed the construction of an innovative vaccine production base based on CHO cell expression system in November 2021, and successfully obtained a vaccine production license issued by the Jiangsu Provincial Drug Administration. The production base has been issued compliance declarations by EU Qualified Persons (QP) for several consecutive years. With a total construction area of approximately 17,000 square meters, this base can be used to produce multiple innovative vaccines, including the new adjuvant recombinant herpes zoster vaccine (CHO cell).